Motif Bio plc (MTFB) Receives Buy Rating from FinnCap
Motif Bio plc (LON:MTFB)‘s stock had its “buy” rating reaffirmed by equities research analysts at FinnCap in a report released on Wednesday. They presently have a GBX 100 ($1.32) price objective on the stock. FinnCap’s price objective suggests a potential upside of 203.03% from the stock’s current price.
Several other equities analysts have also recently issued reports on the company. Northland Securities reaffirmed a “buy” rating on shares of Motif Bio plc in a research report on Monday, September 18th. Peel Hunt initiated coverage on Motif Bio plc in a research report on Thursday, October 5th. They issued a “buy” rating and a GBX 106 ($1.39) price objective on the stock. Finally, Beaufort Securities reaffirmed a “speculative buy” rating and issued a GBX 110 ($1.45) price objective on shares of Motif Bio plc in a research report on Monday, October 2nd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Motif Bio plc presently has an average rating of “Buy” and a consensus target price of GBX 101.50 ($1.33).
Shares of Motif Bio plc (MTFB) opened at GBX 33 ($0.43) on Wednesday. Motif Bio plc has a 52 week low of GBX 21.44 ($0.28) and a 52 week high of GBX 51.75 ($0.68).
WARNING: “Motif Bio plc (MTFB) Receives Buy Rating from FinnCap” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/11/22/motif-bio-plc-mtfb-receives-buy-rating-from-finncap.html.
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Stock Ratings for Motif Bio plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio plc and related stocks with our FREE daily email newsletter.